| (USD) | Dec 2023 | Q/Q |
|---|---|---|
| Revenue | 275.8MM | +2% |
| Operating Income | -43.3MM | -82% |
| Operating Expenses | 319.1MM | - |
| Net Income | -52.8MM | -80% |
| R&D | 29.5MM | +93% |
| G&A | 90.5MM | +5% |
| Amortization | 16.2MM | -1% |
| Interest Expense | 21.7MM | +10% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
GAITHERSBURG, Md., April 22, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Wednesday, May 1, 2024, at 5:00 pm eastern time to discuss the financial results for the first quarter 2024, key business updates, revenue guidance for the second quarter of 2024, and financial outlook for full year 2024. Conference Call InformationParticipants can access the conference call live via webcast. To participate via telephone, please register in advance at this
Key Insights Significantly high institutional ownership implies Emergent BioSolutions' stock price is sensitive to...
Appoints Abigail “Abbey” Jenkins, a veteran biotech executive with over 20 years of experience in commercial leadership, to Board of DirectorsWARREN, N.J., April 01, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the appointment of Abigail Jenkins to the Company’s Board of Direct
As the first-ever U.S. Food and Drug Administration (FDA) approved over-the-counter (OTC) naloxone in 2023, Emergent is working to expand access with NARCAN® Nasal Spray and build on its longstanding efforts with public interest entities across the country Hundreds of thousands of NARCAN® Nasal Spray cartons are available in over 32,000 retail locations in the U.S., and Emergent is working to increase reach into workplaces, businesses and other locationsApproximately 22 million doses of NARCAN®
GAITHERSBURG, Md., March 25, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced that the U.S. Food and Drug Administration (FDA) has listed “No Action Indicated” or NAI status classification for the company's Baltimore Bayview manufacturing facility. Based on this outcome, the Baltimore Bayview facility is considered to be in an acceptable state of compliance with regard to current good manufacturing practices (cGMP). “Quality and compliance excellence remains a top priori
Net Loss Narrows in Q4; Full Year Revenues Hit Guidance Mid-Point
Emergent (EBS) reports mixed earnings for fourth-quarter 2023. The company signs a forbearance agreement with its lenders, effective till April 2023-end.
Emergent BioSolutions Inc. (NYSE:EBS) Q4 2023 Earnings Call Transcript March 6, 2024 Emergent BioSolutions Inc. misses on earnings expectations. Reported EPS is $-0.77 EPS, expectations were $-0.33. Emergent BioSolutions Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon, […]
Q4 2023 Emergent BioSolutions Inc Earnings Call
EBS earnings call for the period ending December 31, 2023.